Bryant Curtis M, Henderson Randal H, Nichols R Charles, Mendenhall William M, Hoppe Bradford S, Vargas Carlos E, Daniels Thomas B, Choo C Richard, Parikh Rahul R, Giap Huan, Slater Jerry D, Vapiwala Neha, Barrett William, Nanda Akash, Mishra Mark V, Choi Seungtaek, Liao Jay J, Mendenhall Nancy P
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Int J Part Ther. 2021 Apr 12;8(2):1-16. doi: 10.14338/IJPT-20-00031.1. eCollection 2021 Fall.
Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and insurers has raised questions regarding its value. Multiple prospective and retrospective studies have been published documenting the efficacy and safety of proton therapy for patients with localized prostate cancer and for patients requiring adjuvant or salvage pelvic radiation after surgery. The Particle Therapy Co-Operative Group (PTCOG) Genitourinary Subcommittee intends to address current proton therapy indications, advantages, disadvantages, and cost effectiveness. We will also discuss the current landscape of clinical trials. This consensus report can be used to guide clinical practice and research directions.
质子治疗在前列腺癌的治疗中是一种有前景但存在争议的疗法。尽管与光子放射治疗相比,它在剂量学方面具有优势,但其给患者和保险公司带来的成本增加引发了对其价值的质疑。已经发表了多项前瞻性和回顾性研究,记录了质子治疗对局限性前列腺癌患者以及术后需要辅助或挽救性盆腔放疗患者的疗效和安全性。粒子治疗合作组(PTCOG)泌尿生殖系统小组委员会打算探讨当前质子治疗的适应症、优点、缺点和成本效益。我们还将讨论当前的临床试验情况。这份共识报告可用于指导临床实践和研究方向。